• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Helo Corp Welcomes Kevin Fuller as President of Helo AI

    12/12/23 8:30:00 AM ET
    $NUS
    $USNA
    Other Pharmaceuticals
    Health Care
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $NUS alert in real time by email

    SAN FRANCISCO, CA / ACCESSWIRE / December 12, 2023 / Helo Corp. (OTC:HLOC) ("Helo" or the "Company") is pleased to announce that Kevin Fuller has joined its executive team as president of Helo AI and chief marketing officer of Helo, effective December 1, 2023.

    "We are delighted to welcome Kevin to our executive team," said Seán McVeigh, Helo's chief executive officer. "Kevin brings significant product development and marketing experience, arising from his previous roles as a senior executive with other leading technology and wellness companies. His passion and leadership add to the significant momentum of our Helo AI platform and upcoming products."

    Mr. Fuller, 53, served as cofounder and chief executive officer of MACUVU Macular Health from 2022 to 2023. From 2005 to 2021, he served as Senior Vice President of Global Product & Brand, and in other roles at Nu Skin (NYSE:NUS). From 1997 to 2005, Mr. Fuller served as Senior Product Manager at USANA (NYSE:USNA). Mr. Fuller received an M.B.A. degree from Brigham Young University and a B.S. in Biology from the University of Utah.

    "Helo is transforming the wellness technology category through integration of biodata, artificial intelligence and personalized nutrition," said Mr. Fuller. "The Company's history of innovation and focus on data-driven wellness are very compelling, but Helo's future wellness ecosystem will transcend current digital wellness solutions. I am excited to join the talented Helo team in building the future of wellness and nutrition powered by AI."

    About Helo Corp.

    Helo Corp. (OTC:HLOC)  is a data-driven wellness technology company. Helo wearables and other smart devices are built on Helo's Life Sensing Technology®, which uses state-of-the-art sensors, enhanced signal processing, and algorithms to collect and process specific bio-parameters. Helo is developing the Helo AI platform to leverage artificial intelligence and other technologies to analyze wearer data to provide recommendations that support the adoption of healthier lifestyle choices to drive human wellness transformation.

    For more information please visit helocorp.com.

    The Company's disclosure statements and financial statements are available at OTC PINK:HLOC.

    Forward Looking Statements

    This news release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will," and similar statements. All statements other than statements of historical fact in this press release are forward-looking statements and involve certain risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. These forward-looking statements are based on management's current expectations, assumptions, estimates and projections about the Company and the industry in which the Company operates, but involve a number of unknown risks and uncertainties. Further information regarding these and other risks is included in the Company's filings with the OTC Markets and the Securities and Exchange Commission. The Company undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and actual results may differ materially from the anticipated results. You are urged to consider these factors carefully in evaluating the forward-looking statements contained herein and are cautioned not to place undue reliance on such forward-looking statements, which are qualified in their entirety by these cautionary statements.

    Investors Contact:
    [email protected]
    650-646-2193

    SOURCE: Helo Corp.



    View the original press release on accesswire.com

    Get the next $NUS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NUS
    $USNA

    CompanyDatePrice TargetRatingAnalyst
    USANA Health Sciences Inc.
    $USNA
    6/23/2023Buy
    Sidoti
    Nu Skin Enterprises Inc.
    $NUS
    1/31/2023$43.00 → $39.00Buy → Hold
    Jefferies
    USANA Health Sciences Inc.
    $USNA
    7/7/2022$78.00 → $53.00Hold → Underperform
    Jefferies
    USANA Health Sciences Inc.
    $USNA
    4/14/2022$86.00Neutral
    DA Davidson
    Nu Skin Enterprises Inc.
    $NUS
    2/17/2022$47.00 → $50.00Neutral
    DA Davidson
    Nu Skin Enterprises Inc.
    $NUS
    11/24/2021$43.00 → $49.00Neutral
    Citigroup
    Nu Skin Enterprises Inc.
    $NUS
    10/6/2021$61.00 → $47.00Neutral
    DA Davidson
    More analyst ratings

    $NUS
    $USNA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Tested, Trusted, Approved: USANA CellSentials Earns ConsumerLab.com Seal of Approval for Purity and Potency

    SALT LAKE CITY, March 24, 2026 /PRNewswire/ -- USANA (NYSE:USNA), a global leader in cellular nutrition, today announced that its flagship CellSentials supplement has earned the prestigious ConsumerLab.com Seal of Approval. This highly respected third-party certification is awarded only to products that meet rigorous standards for purity, potency, and label accuracy. Recent health surveys indicate that many Americans fall short in key nutrients—including vitamins A, C, D, and E, as well as zinc and magnesium—making daily supplementation an important tool for supporting overall w

    3/24/26 7:02:00 AM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    Nu Skin Enterprises Appoints Chelsea Lantz as Interim Chief Financial Officer

    Nu Skin Enterprises, Inc. (NYSE:NUS) today announced the appointment of Chelsea Lantz as interim Chief Financial Officer, effective immediately. The appointment of Lantz comes after James Thomas stepped down as CFO to pursue an outside opportunity. "On behalf of our board, management and the entire Nu Skin team, we thank James for his leadership and significant contributions over 16 years at Nu Skin and wish him and his family well in their future pursuits," said Ryan Napierski, president and CEO. "We have a talented finance team who has led the ongoing work to improve our operational performance and strengthen our balance sheet over the past year. I am excited to work directly with Chels

    3/20/26 4:05:00 PM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    Nu Skin Appoints Chayce Clark as COO

    Clark to expand on his responsibilities as chief legal officer to oversee company operational functions and revenue performance Nu Skin Enterprises Inc. (NYSE:NUS) today announced the appointment of Chayce Clark as chief operating officer effective immediately. Clark will be responsible for leading the company's revenue performance and end-to-end operational execution across the business in addition to maintaining his role as the company's chief legal officer. "Chayce has been a valuable part of our executive team and an important voice in our efforts to become the world's leading intelligent beauty and wellness leadership opportunity platform," said Ryan Napierski, president and CEO. "

    3/9/26 4:05:00 PM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    $NUS
    $USNA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Fuller Gilbert A

    4 - USANA HEALTH SCIENCES INC (0000896264) (Issuer)

    3/20/26 4:53:49 PM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    Director Woodbury Edwina D was granted 14 shares, increasing direct ownership by 0.03% to 42,993 units (SEC Form 4)

    4 - NU SKIN ENTERPRISES, INC. (0001021561) (Issuer)

    3/12/26 5:03:45 PM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    EVP, President of Global Sales Keisel Justin S was granted 47,059 shares, increasing direct ownership by 42% to 160,170 units (SEC Form 4)

    4 - NU SKIN ENTERPRISES, INC. (0001021561) (Issuer)

    3/9/26 6:14:06 PM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    $NUS
    $USNA
    SEC Filings

    View All

    Nu Skin Enterprises Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - NU SKIN ENTERPRISES, INC. (0001021561) (Filer)

    3/20/26 4:16:06 PM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    SEC Form 10-K filed by USANA Health Sciences Inc.

    10-K - USANA HEALTH SCIENCES INC (0000896264) (Filer)

    3/16/26 2:57:18 PM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    Nu Skin Enterprises Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - NU SKIN ENTERPRISES, INC. (0001021561) (Filer)

    3/9/26 4:16:23 PM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    $NUS
    $USNA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Sidoti initiated coverage on USANA

    Sidoti initiated coverage of USANA with a rating of Buy

    6/23/23 9:12:38 AM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    Nu Skin downgraded by Jefferies with a new price target

    Jefferies downgraded Nu Skin from Buy to Hold and set a new price target of $39.00 from $43.00 previously

    1/31/23 6:17:27 AM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    USANA downgraded by Jefferies with a new price target

    Jefferies downgraded USANA from Hold to Underperform and set a new price target of $53.00 from $78.00 previously

    7/7/22 9:35:48 AM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    $NUS
    $USNA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Product Officer Hatchett Steven Keith bought $52,855 worth of shares (5,500 units at $9.61), increasing direct ownership by 3% to 167,565 units (SEC Form 4)

    4 - NU SKIN ENTERPRISES, INC. (0001021561) (Issuer)

    11/12/25 4:32:45 PM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    Chief Product Officer Hatchett Steven Keith bought $49,010 worth of shares (6,500 units at $7.54), increasing direct ownership by 4% to 162,065 units (SEC Form 4)

    4 - NU SKIN ENTERPRISES, INC. (0001021561) (Issuer)

    5/28/25 6:26:44 PM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    $NUS
    $USNA
    Leadership Updates

    Live Leadership Updates

    View All

    Nu Skin Enterprises Appoints Chelsea Lantz as Interim Chief Financial Officer

    Nu Skin Enterprises, Inc. (NYSE:NUS) today announced the appointment of Chelsea Lantz as interim Chief Financial Officer, effective immediately. The appointment of Lantz comes after James Thomas stepped down as CFO to pursue an outside opportunity. "On behalf of our board, management and the entire Nu Skin team, we thank James for his leadership and significant contributions over 16 years at Nu Skin and wish him and his family well in their future pursuits," said Ryan Napierski, president and CEO. "We have a talented finance team who has led the ongoing work to improve our operational performance and strengthen our balance sheet over the past year. I am excited to work directly with Chels

    3/20/26 4:05:00 PM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    Nu Skin Appoints Chayce Clark as COO

    Clark to expand on his responsibilities as chief legal officer to oversee company operational functions and revenue performance Nu Skin Enterprises Inc. (NYSE:NUS) today announced the appointment of Chayce Clark as chief operating officer effective immediately. Clark will be responsible for leading the company's revenue performance and end-to-end operational execution across the business in addition to maintaining his role as the company's chief legal officer. "Chayce has been a valuable part of our executive team and an important voice in our efforts to become the world's leading intelligent beauty and wellness leadership opportunity platform," said Ryan Napierski, president and CEO. "

    3/9/26 4:05:00 PM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    Kevin Guest Returns to USANA Health Sciences as CEO

    USANA Health Sciences, Inc. (NYSE:USNA) announced today a leadership transition as part of the Company's ongoing commitment to accelerating growth and enhancing shareholder value. Kevin Guest is returning to lead the Company as Chief Executive Officer, effective immediately. Mr. Guest, who has spent more than three decades at the Company, including eight years as CEO and the last three years as Executive Chairman, has agreed to again serve as USANA's CEO and will continue serving as Chairman. Mr. Guest succeeds Jim Brown, who has stepped down from his position of CEO and President. "We thank Jim for his contributions and his leadership over the past 19 years and in his role as CEO over th

    1/8/26 9:00:00 AM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    $NUS
    $USNA
    Financials

    Live finance-specific insights

    View All

    Next-Generation Platforms Scale Across Energy, Wellness, and Smokeless Consumer Segments

    Issued on behalf of Doseology Sciences Inc.Equity-Insider.com VANCOUVER, BC, March 5, 2026 /CNW/ -- Consumers are voting with their wallets, and zero-sugar is winning. Zero-sugar beverages are driving 6x more dollar growth than regular varieties as buyers actively choose clean-label products with natural sweeteners and functional ingredients[1]. The global market is forecast to expand from $350 billion in 2024 toward $500 billion by 2029, fueled by health-conscious consumers who want naturally functional products without heavy processing[1]. This structural shift is creating validated demand for precision-dosed, portable formats across energy and wellness categories, positioning Doseology Sc

    3/5/26 9:00:00 AM ET
    $HLF
    $NHTC
    $NMTC
    Other Pharmaceuticals
    Health Care
    Consumer Specialties
    Consumer Discretionary

    USANA Health Sciences Reports Fourth Quarter and Full Year 2025 Results and Provides Fiscal Year 2026 Outlook

    USANA Health Sciences, Inc. (NYSE:USNA) today announced financial results for its fiscal fourth quarter and fiscal year ended January 3, 2026. Key Financial and Operating Results   Q4 2025   Q4 2024   FY 2025   FY 2024 Net sales $226.2   $213.6   $925.3   $854.5 Net (loss) earnings* $-1.8   $4.5   $10.8   $42.0 Diluted EPS $-0.10   $0.23   $0.58   $2.19 Adjusted diluted EPS(1) $0.60   $0.64   $1.93   $2.59 Adjusted EBITDA(2) $27.3

    2/17/26 4:15:00 PM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    Nu Skin Enterprises Reports Fourth Quarter and Full-year 2025 Results Within Guidance

    Company provides initial outlook for Q1 and fiscal year 2026, forecasting a return to revenue growth by year's end Nu Skin Enterprises Inc. (NYSE:NUS) today announced fourth quarter and full-year 2025 revenue and earnings within guidance with more than 50% growth in earnings for 2025. Executive Summary Q4 2025 vs. Prior-year Quarter Revenue $370.3 million; (16.9)% or (10.4)% excluding Mavely 2024 revenue (0.2)% FX impact or $(0.8) million Earnings Per Share (EPS) $0.29 compared to $(0.73) or $0.38 excluding restructuring and other charges Customers 748,796; (10)% Paid Affiliates 129,311; (11)% Sales Leaders 30,045; (

    2/12/26 4:06:00 PM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    $NUS
    $USNA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Nu Skin Enterprises Inc.

    SC 13G/A - NU SKIN ENTERPRISES, INC. (0001021561) (Subject)

    11/12/24 4:47:17 PM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    Amendment: SEC Form SC 13G/A filed by Nu Skin Enterprises Inc.

    SC 13G/A - NU SKIN ENTERPRISES, INC. (0001021561) (Subject)

    11/6/24 10:20:59 AM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    Amendment: SEC Form SC 13G/A filed by Nu Skin Enterprises Inc.

    SC 13G/A - NU SKIN ENTERPRISES, INC. (0001021561) (Subject)

    11/4/24 10:21:31 AM ET
    $NUS
    Other Pharmaceuticals
    Health Care